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Deena J. Chisolm, PhD,† Gitit Tomer, MD,k and Wallace V. Crandall, MD,* for the ImproveCareNow
Pediatric IBD Learning Health System
Background: Racially disparate care has been shown to contribute to suboptimal health care outcomes for minorities. Using the ImproveCareNow
network, we investigated differences in management and outcomes of pediatric patients with Crohn’s disease at diagnosis and 1-year postdiagnosis.
Methods: ImproveCareNow is a learning health network for pediatric inflammatory bowel disease. It contains prospective, longitudinal data from
outpatient encounters. This retrospective study included all patients with Crohn’s disease #21 years, September 2006 to October 2014, with the first
recorded encounter #90 days from date of diagnosis and an encounter 1 year 660 days. We examined the effect of race on remission rate and treatment
at diagnosis and 1 year from diagnosis using t-tests, Wilcoxon rank-sum tests, x2 statistic, and Fisher’s exact tests, where appropriate, followed by
univariate regression models.
Results: Nine hundred seventy-six patients (Black ¼ 118 (12%), White ¼ 858 (88%), mean age ¼ 13 years, 63% male) from 39 sites were included.
Black children had a higher percentage of Medicaid insurance (44% versus 11%, P , 0.001). At diagnosis, Black children had more active disease
according to physician global assessment (P ¼ 0.027), but not by short Pediatric Crohn’s Disease Activity Index (P ¼ 0.67). Race differences in
treatment were not identified. Black children had lower hematocrit (34.8 versus 36.7, P , 0.001) and albumin levels (3.6 versus 3.9, P ¼ 0.001). At 1
year, Black children had more active disease according to physician global assessment (P ¼ 0.016), but not by short Pediatric Crohn’s Disease Activity
Index (P ¼ 0.06).
Conclusions: Black children with Crohn’s disease may have more severe disease than White children based on physician global assessment. Neither
disease phenotype differences at diagnosis nor treatment differences at 1-year follow-up were identified.
(Inflamm Bowel Dis 2017;23:767–774)
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S ignificant racial, ethnic, and socioeconomic disparities inaccess to health care and quality of care have been found
throughout the United States in a variety of conditions with little
improvement in disparities being reported in the past decade.1–4
Disparities have been shown to contribute to inefficiencies in
health care delivery systems, as well as suboptimal health care
outcomes for minorities and low-income groups.5–7 For
some minority groups, access to medical care may be decreased,
and different patterns of health care–seeking behavior may also
play a role.7,8
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Racial, ethnic, and socioeconomic disparities have been
reported in adult inflammatory bowel disease (IBD) populations in
rates of surgery and hospitalization. A recent study using a nationally
representative population found that non-Hispanic Blacks experi-
enced disproportionately higher rates of IBD-related hospitalizations
and mortality, relative to the prevalence of IBD.9 There is some
evidence for racial disparities in the medical management of adult
IBD, with Flaser et al10 reporting that Black patients with IBD were
half as likely as Whites to receive infliximab, and 43% less likely to
be treated with 6-mercaptopurine/azathioprine.
Disparities have also been suggested in pediatric IBD,
including the utilization of parenteral nutrition in children
hospitalized for protein-calorie malnutrition,11 hospitalization
and surgery rates for children with Crohn’s disease (CD),12 and
postoperative complications for children with ulcerative colitis.13
However, other studies have shown minimal differences.14 Sim-
ilarly, studies looking at differences in disease severity and rates
of perianal disease are conflicting.6,15,16 Eidelwein et al17 sug-
gested that there are differences between Black and White chil-
dren with IBD in disease phenotype and family history, but little
is known about the role of biological differences in the medical
management and outcomes of children with IBD.
Identifying health care disparities is an essential step in
allowing practitioners to improve outcomes and health care
delivery. Using data from the ImproveCareNow (ICN) network,
we aimed to address gaps in the literature on health care
disparities in pediatric patients with CD. The ICN registry is
poised to address some of these gaps as it contains prospective,
detailed, longitudinal demographic, disease, and treatment data
collected during outpatient encounters for a large number of
pediatric patients with CD across a wide geographical range. Of
particular relevance to this study, ICN includes information about
disease severity and payor type, which has also been linked to
disparities in access and quality of care in the treatment of IBD.18
The primary purpose of this study was to investigate the
topic of race disparities in the pediatric IBD population, specifically
between Black and White pediatric patients with IBD. The main
objectives of our study were to determine (1) if the medical
management of Black children with CD differs fromWhite children
at diagnosis and 1-year postdiagnosis; and (2) if Black children are
less likely to be in corticosteroid-free remission than White children
at 1-year postdiagnosis. Our hypotheses were (1) Black children
with CD will have a more severe, extensive disease presentation at
diagnosis and 1-year follow-up compared with White children, and
(2) Black children will have lower rates of steroid-free remission
and continuous remission compared with White children.
METHODS
Data Source and Study Design
We performed a retrospective cohort study of pediatric
patients with CD who were enrolled in ICN. ICN is a learning
health network of pediatric gastroenterology practices established
in 2007 to improve the health and health care of children and
adolescents with IBD. The ICN registry contains demographic,
disease, and treatment data collected prospectively and longitu-
dinally during outpatient encounters. Patients are diagnosed and
managed according to the usual practice of the primary gastro-
enterologist, and quality improvement methodologies are applied
within centers.
Study Population
ICN registry data were extracted for all visits between
September 2006 and October 2014 for all patients with CD.
Patients were included if they were managed at an ICN center
within the defined study period, had a diagnosis of CD, were
enrolled in the ICN registry within 90 days of CD diagnosis, were
of Black or White race (as recorded by each individual center
without predetermined network-wide criteria; biracial and multira-
cial subjects were excluded given a limited sample size), had
gender recorded, and had at least 1-year follow-up. Other than
insurance status, there were no other socioeconomic variables
within the database for analysis. Our final study population
consisted of individuals who had data at both diagnosis and
1-year postdiagnosis.
Data were recorded and analyses performed for the
encounter closest to date of diagnosis (if within 90 days of
diagnosis) and at the encounter closest to 1-year postdiagnosis
(within 60 days). We counted all visits during the first year to
assess frequency of follow-up. Data elements for this study
included basic demographics, payor type, disease duration,
disease extent as defined by Paris classification,19 laboratory
studies (hematocrit, erythrocyte sedimentation rate (ESR), and
albumin), medications (5-aminosalicylates, corticosteroid,
6-mercaptopurine/azathioprine, methotrexate, anti–tumor necrosis
FIGURE 1. Study flowchart.
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factor a, antibiotics, and enteral nutrition), nutrition and growth
status (assigned by the provider as satisfactory, at risk, or in
failure according to standardized criteria), body mass index and
percentile, growth status, physician global assessment (PGA, pro-
vider assigns to remission, mild, moderate, or severe category),
and short Pediatric Crohn’s Disease Activity Index (sPCDAI).20
Exposures and Outcomes
The primary predictor in this study was race (Black,
White), and the primary outcomes were remission rate (by
PGA) and medical management, at diagnosis and at the 1-year
follow-up visit.
Patient insurance payor status was a secondary predictor.
Secondary outcomes included remission rate by sPCDAI, growth
and nutritional status, laboratory results (hematocrit, ESR, and
albumin), disease course (number of visits in remission during the
first year) and extent, at diagnosis and the 1-year follow-up visit.
Annual visit frequency was also assessed. Fecal calprotectin was
not routinely collected and, therefore, could not be evaluated. C-
reactive protein was routinely collected; however, because of
varying methodology and normal ranges across participating
centers, as well as the possibility that Black and White children
used different laboratories, these data could not be evaluated.
For ethnicity, which was asked differently in 2 different
data collection forms, subjects were excluded when they specif-
ically endorsed “Hispanic or Latino.” For a small subset of
subjects (17 Black and 60 White) with anomalous height scores
(i.e., scores that deviated significantly from a smoothed height
trajectory), body mass index scores were recomputed using inter-
polated height scores from surrounding visits.
Statistical Analyses
We used t-tests or Wilcoxon rank-sum (nonparametric)
tests, as appropriate, to compare age at diagnosis, disease dura-
tion, length of enrollment in the study, education levels, and
laboratory study results between Black and White children. Cat-
egorical variables for health insurance status, nutritional and
growth status, medication usage, Paris classifications, and PGA
and sPCDAI categories were compared using the x2 statistic or
Fisher’s exact test, as appropriate. The Wilcoxon rank-sum test
was used to evaluate race difference for nonnormally distributed
variables. When race differences were identified, we conducted
univariate regression models with race as a predictor, as well as
separate univariate models with payor status as a predictor. Sub-
ject’s age at the visit was included as a covariate when this vari-
able demonstrated significance in a preliminary univariate
regression model with age as the only predictor. This was fol-
lowed by univariate regression with race stratified by payor status
to investigate potential effect modification. We also performed
a bivariate interaction model to formally test for effect modifica-
tion based on the significance of the interaction term (data not
shown).
TABLE 1. Demographic Characteristics by Race at Diagnosis and Remission Status Within the First Year
Black White P
Total, n 118 858
Male, n (%) 69 (58) 544 (63) 0.35
At diagnosis
Age (yr), M [SD] 13.2 [3.1] 12.9 [3.3] 0.19
Disease duration (d), Mdn [Q1-Q3] 24 [14–44] 26 [14–45] 0.96
Parental educationa, n (%) 6 (75) 41 (84) 0.62
Insuranceb
Medicaid, n (%) 44 (44) 80 (11) ,0.001
Commercial, n (%) 56 (56) 664 (89)
Within the first year
Visits, M [SD] 5.9 [2.4] 6.2 [2.4] 0.09
Visits in remission (PGA)c, M [SD] 2.7 [1.8] 3.4 [1.9] ,0.001
Visits in remission (sPCDAI)d, M [SD] 1.6 [1.7] 2.3 [1.9] ,0.001
Visits in corticosteroid-free remission (PGA)c, M [SD] 2.1 [1.7] 2.6 [1.6] 0.002
Visits in corticosteroid-free remission (sPCDAI)d, M [SD] 1.3 [1.5] 1.7 [1.6] 0.002
Column percentages are presented by race and based on available data. Bolded P values represent significant findings.
aParental education refers to number and percentage of subjects with at least 1 parent with some college education; only 6% of all subjects responded.
bThree Black and 12 White subjects with both Medicaid and commercial insurance were excluded from this analysis, as well as those who did not respond or were unaware of their
insurance type.
cRemission status according to PGA.
dRemission status according to sPCDAI (sPCDAI , 15 ¼ remission).
M, mean; Mdn, median.
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Post hoc subanalyses were performed. A survival analysis
using Kaplan–Meier curves and Cox proportional hazard model
were used to compare time to onset for the use of biological
medication according to race. We also evaluated whether Black
children were more at risk for nonresponse to a biologic. Using
the Fisher’s exact test, we compared the discontinuation of
a biologic among those subjects who initiated a biologic within
the first year since diagnosis by race. We defined biological dis-
continuation by having two subsequent visits where a biologic
was not listed as a medication.
A P-value of ,0.05 was considered statistically significant,
unless otherwise noted. All statistical analyses were performed
using R 3.0.1 (R Foundation for Statistical Computing, 2013).
This study was approved by the Nationwide Children’s Hospital
Institutional Review Board.
RESULTS
Demographics
Figure 1 depicts the study flowchart which resulted in
the final patient cohort. Approximately, the same proportion
of Black and White children were excluded for lacking a visit
at 1-year follow-up within the 60-day window (Black ¼ 82.6%,
TABLE 2. Disease Behavior and Extent at Diagnosis and 1-year Follow-up
At Diagnosis 1-year Follow-upa
Black, n (%) White, n (%) P Black, n (%) White, n (%) P
Nutritional status
Satisfactory 82 (73) 617 (76) 93 (83) 720 (85)
At risk 21 (19) 146 (18) 15 (13) 102 (12)
In failure 9 (8) 52 (6) 0.77 4 (4) 23 (3) 0.68
BMI, Mdn [IQR] 17.9 [15.9–20.6] 17.8 [16.1–20.1] 0.77 19.3 [17.4–21.7] 19.3 [17.0–21.9] 0.50
BMI %ile, Mdn [IQR] 35.7 [17.3–71.5] 42.8 [19.6–69.2] 0.72 56.8 [29.5–78.3] 53.6 [27.3–79.4] 0.58
Growth status
Satisfactory 87 (80) 672 (83) 0.09 88 (81) 721 (90) 0.002
At risk 11 (10) 101 (12) 12 (11) 61 (8)
In failure 11 (10) 41 (5) 8 (7) 16 (2)
Paris classification
L1: distal 1/2 ileum 6 limited cecal 4 (10) 64 (19) 0.24 9 (14) 99 (20) 0.32
L2: colonic 10 (24) 59 (18) 15 (23) 85 (17)
L3: ileocolonic 27 (66) 210 (63) 41 (63) 319 (63)
L4a: upper disease proximal to the ligament of Treitz 17 (45) 155 (52) 0.53 26 (46) 205 (46) 1.00
L4b: upper disease distal to the ligament of Treitz 2 (6) 19 (8) 1.00 1 (2) 42 (11) 0.045
L4a and 4b 4 (11) 35 (13) 1.00 6 (10) 56 (12) 0.81
Behavior
B1: nonstricturing, nonpenetrating 95 (85) 736 (89) 0.24 86 (85) 677 (87) 0.69
B2: stricturing 6 (5) 40 (5) 1.00 10 (10) 47 (6) 0.21
B3: penetrating 8 (7) 40 (5) 0.42 4 (4) 32 (4) 1.00
B2B3: penetrating and stricturing 3 (3) 10 (1) 0.20 1 (1) 21 (3) 0.50
Perianal 22 (20) 151 (19) 0.88 29 (25) 176 (21) 0.40
PGA
In remission 32 (29) 287 (35) 0.027 71 (63) 633 (75) 0.016
Mild 40 (37) 354 (43) 29 (26) 162 (19)
Moderate-severe 37 (34) 184 (22) 12 (11) 47 (6)
sPCDAI
Inactive 34 (47) 300 (52) 0.67 46 (65) 454 (73) 0.060
Mild 19 (26) 134 (23) 12 (17) 110 (18)
Moderate-severe 20 (27) 141 (25) 13 (18) 58 (9)
Bolded P values represent significant findings.
aOne-year follow-up refers to visit closest to 365 days (660 days) from diagnosis for each variable—except perianal which refers to all visits up to and including the 1-year follow-up.
BMI, body mass index; IQR, interquartile range; Mdn, median.
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White ¼ 83.1%). Our final study population included 976
pediatric patients with CD from 39 centers, which was com-
posed of 63% males (n ¼ 613), with a mean age of 13 years
(Table 1). There were no significant race differences for sex or
age at diagnosis. A higher percentage of Black patients had
Medicaid as their primary payor and a higher percentage of
White children were using commercial insurance (P , 0.001,
Table 1).
Primary Outcomes
Remission Rate/Disease Activity
By PGA classification, Black children were less likely to be
in remission (Black children 29%, White children 35%) and more
likely to have moderate-to-severe disease activity (Black children
34%, White children 22%) at diagnosis (P ¼ 0.027). Similar
results were seen at 1-year follow-up (P ¼ 0.016). (Table 2 and
Figure 2).
Medical Management
There were no significant differences in medications
recorded at the time of diagnosis, 1-year follow-up visit, or from
all visits collectively within the first year (Table 3).
Secondary Outcomes
Remission Rate/Disease Activity by sPCDAI
In contrast to the PGA noted previously, there were no
significant race differences in remission rate/disease activity at
baseline or at 1 year (Table 2 and Figure 2).
Growth and Nutrition Status
There were no race differences in nutritional status at
baseline or at 1-year follow-up. White children had higher rates of
satisfactory growth and lower rates of growth failure at 1-year
follow-up (P ¼ 0.002, Table 2).
Laboratory Evaluation
At both diagnosis and 1-year follow-up, Black children had
statistically lower hematocrit and albumin levels compared with
White children, and a higher ESR at 1 year, each with small-to-
medium effect sizes based on Cohen’s d (Table 4).
Disease Course and Extent
There was no difference in the mean number of visits
within the first year by race (Black children 5.9 visits, White
children 6.2 visits, P ¼ 0.09). However, Black children had fewer
visits in remission (P , 0.001) or corticosteroid-free remission
(P ¼ 0.002) within the first year based on PGA and sPCDAI
(Table 1). There were no differences in disease behavior (includ-
ing perianal disease). L4b (upper disease distal to the ligament of
Treitz) was more common in White children (P ¼ 0.045, Table 2).
FIGURE 2. Disease Severity at diagnosis and 1-year follow-up ac-
cording to race. Disease severity defined according to PGA and
sPCDAI.
TABLE 3. Medicationsa by Race at Diagnosis, 1 Year, and Time From Diagnosis to 1 Year
Diagnosis 1 Year Diagnosis to 1 Year
Black, n (%) White, n (%) P Black, n (%) White, n (%) P Black, n (%) White, n (%) P
5-ASA 38 (32) 305 (36) 0.54 38 (32) 276 (32) 1.00 51 (43) 390 (45) 0.72
Corticosteroid 69 (58) 521 (61) 0.71 8 (7) 87 (10) 0.32 85 (72) 612 (71) 0.96
6-MP/AZA 38 (32) 293 (34) 0.75 56 (47) 376 (44) 0.52 73 (62) 515 (60) 0.78
Methotrexate 3 (3) 28 (4) 1.00 7 (7) 84 (11) 0.26 8 (8) 103 (15) 0.12
Anti-TNF a 13 (12) 88 (11) 0.94 37 (35) 255 (33) 0.69 39 (41) 289 (42) 0.99
Antibiotics 18 (17) 104 (14) 0.43 8 (8) 52 (7) 0.88 30 (32) 222 (32) 1.00
Enteral nutrition 3 (3) 18 (3) 0.73 0 (0) 9 (1) 0.61 3 (3) 36 (4) 0.62
aMedications at diagnosis include medications prescribed within 90 days of diagnosis; diagnosis to 1 year refers to having at least 1 visit within that time frame.
5-ASA, 5-aminosalicylates; 6-MP, 6-mercaptopurine; Anti–tumor necrosis factor (TNF) a, infliximab, adalimumab, certolizumab; antibiotics, ciprofloxacin, metronidazole, rifaximin;
AZA, azathioprine.
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Univariate Regression Models for
Significant Outcomes
Univariate logistic regression demonstrated that Black
children were less likely to have at least 1 visit in remission or
corticosteroid-free remission within the first year (based on both
PGA and sPCDAI), have satisfactory growth at 1 year, and be in
remission at 1 year based on PGA (Table 5).
Regression models predicting laboratory measures from
race indicate lower hematocrit and albumin levels for Black
children compared with White children at both diagnosis and 1-
year follow-up. Children with public insurance were less likely to
have at least 1 visit in remission within the first year (based on
PGA) and had lower albumin levels at 1-year follow-up compared
with those with private insurance.
When stratifying by payor status, among those with public
insurance, a lower proportion of Black children had visits in
remission and visits in corticosteroid-free remission (based on
PGA and sPCDAI), and Black children were less likely to be in
remission at 1 year based on PGA. Across all measures, no effect
modification of race based on payor status was identified—as
indicated by nonsignificant interaction terms in bivariate interac-
tion models across all measures (see Appendix 1, Supplemental
Digital Content 1, http://links.lww.com/IBD/B460).
Subanalysis
There was no difference in the time to initiation of first
biological medication according to race (odds ratio ¼ 1.04 [95%
CI, 0.74–1.45]) (Fig. 3). There was no difference in the proportion
of biological discontinuation according to race (number discon-
tinued: Black children ¼ 0, White children ¼ 20, Fisher’s exact
test: P ¼ 0.15).
DISCUSSION
In pediatric patients with CD, the literature on disease severity
or treatment discrepancies is sparse. In our study of pediatric patients
with CD within the ICN registry, we found no treatment differences
between the Black and White cohorts, which is similar to the results
of a survey of an adult cohort of patients with IBD, where no
difference in medication by race was noted.7 This is in contrast to
a retrospective review from a single, tertiary care center that found
that Black children were more likely to be prescribed corticosteroids
and infliximab,17 as well as our earlier work in a hospitalized cohort,
in which we found that more Black patients received biological
agents and corticosteroids compared with White patients during
the hospitalization.14 The differences in this study and our previous
work are not necessarily contradictory given the different study
cohorts (inpatient versus outpatient). For example, Black patients
may have been more acutely ill at the time of initiating medications,
necessitating an admission in which they received infliximab or
corticosteroids, whereas White patients had lesser disease severity
and were started on infliximab in the outpatient setting.
Despite no obvious differences in treatment during the first
year, Black patients were less likely to be in remission by PGA at
both baseline (6% difference) and at 1 year (12% difference) and
more likely to have moderate-to-severe disease by PGA at both
baseline (12% difference) and at 1 year (5%). Furthermore,
although there were no differences in remission rate/disease
activity at either time point by sPCDAI, there was a trend toward
a significant difference at 1 year (P ¼ 0.06). Given that the data
were less complete for sPCDAI than those for PGA, failure to
detect a difference in disease activity by sPCDAI at 1 year may
have been related to power.
It is not particularly surprising to have found some
discrepancy between PGA and sPCDAI. Although sPCDAI is
comprised of several specific items used to generate an activity
score, PGA is determined using all the data available to the
provider, including (for good or bad) subtle clinical impressions
that may not be accounted for by the sPCDAI. Both are subjective
measures, and neither is sufficient to accurately predict endo-
scopic remission. In addition, the amount of missing data differed
between the 2 groups as previously noted.
Given the discrepancy in findings between the PGA and
sPCDAI results, it seems reasonable to examine the secondary
outcome measures to help determine whether or not Black patients
experience more active disease in the first year from diagnosis.
TABLE 4. Laboratory Studies by Race at Diagnosis and 1-year Follow-up
Diagnosis 1-year Follow-up
Black White
P
Black White
PMean 6 SD n (%)a Mean 6 SD n (%) Mean 6 SD n (%) Mean 6 SD n (%)
Hematocrit 34.8 6 5.5 96 (81) 36.7 6 4.2 668 (78) ,0.001 36.6 6 5.4 85 (72) 37.9 6 4.2 613 (71) 0.004
ESR 27.2 6 20.2 88 (75) 22.9 6 18.5 581 (68) 0.06 20.0 6 18.8 81 (69) 15.2 6 13.5 534 (62) 0.03
Albumin 3.6 6 0.7 94 (80) 3.9 6 0.6 627 (73) 0.001 3.9 6 0.6 86 (73) 4.2 6 0.5 594 (69) ,0.001
Bolded P values represent significant findings. Cohen’s d for significant results: Hematocrit at diagnosis ¼ 0.39; Hematocrit at 1 year ¼ 0.27; Albumin at diagnosis ¼ 0.46; Albumin at 1
year ¼ 0.54.
aPercentage of subjects with a particular laboratory for each race group.
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Black patients had fewer visits in remission during the first year
from diagnosis, despite a similar number of overall visits. In
addition, Black patients were more likely to be assessed as having
growth delay, and had statistically significant, if not clinically
important, increases in ESR and decreases in albumin and
hematocrit. This is consistent with findings by White et al in
children with CD, and at least 1 preliminary investigation done by
Straus et al in adults with CD showing Black patients had a higher
rate of anemia compared with White patients.7,21 These effects were
found to be unrelated to payor status. Taken collectively, our data
suggest that Black patients may have an increase in disease activity
during the first year of diagnosis, despite similar treatment and
number of follow-up visits. The reasons for this are unclear but
may suggest that CD is more severe in Black children, and/or they
respond less well or less quickly to existing medication options.
There are several limitations of our study. Data are captured at
outpatient clinic encounters only, so there are limited data with
respect to interval events, procedures, surgeries, and hospitalizations.
The results may not apply to patients with ulcerative colitis or to
those who were excluded from the study population. Furthermore,
a significant proportion of subjects were excluded from the final
sample because they did not have visits at both diagnosis and within
the 1-year follow-up window. Most of those excluded were not
enrolled in the ICN registry within 90 days of IBD diagnosis. Factors
TABLE 5. Univariate Regression Models for Significant Outcomes
Univariate: Race and Payor
Race Payor
b SE b ORa b SE b OR
Visits in remission, PGA ($1 versus 0) 21.13b 0.33 0.32 [0.17 to 20.62] 20.80c 0.37 0.45 [0.22–0.93]
Visits in corticosteroid-free remission, PGA ($1 versus 0)d 20.79e 0.27 0.45 [0.27 to 20.76] 20.42 0.29 0.66 [0.38–1.15]
Visits in remission, sPCDAI ($1 versus 0) 20.78b 0.20 0.46 [0.31 to 20.68] 20.43 0.23 0.65 [0.42–1.02]
Visits in corticosteroid-free remission, sPCDAI ($1 versus 0)d 20.65e 0.20 0.52 [0.35 to 20.77] 20.26 0.21 0.77 [0.51–1.17]
Growth at 1 year (satisfactory versus not) 20.76e 0.28 0.47 [0.27 to 20.81] 20.06 0.33 0.94 [0.49–1.80]
PGA at dx (in remission versus not) 20.25 0.22 0.78 [0.50 to 21.21] 20.31 0.22 0.73 [0.48–1.12]
PGA at 1 year (in remission versus not) 20.56e 0.21 0.57 [0.38 to 20.87] 20.31 0.21 0.73 [0.48–1.11]
Hematocrit at dxd 21.89b 0.47 20.29 0.45
Hematocrit at 1 yeard 21.34e 0.49 20.29 0.47
Albumin at dx 20.24b 0.07 20.04 0.07
Albumin at 1 yeard 20.32b 0.06 20.16e 0.05
Univariate: Race Stratified by Payor Status
Public Payor Commercial Payor
b SE b OR b SE b OR
Visits in remission, PGA ($1 versus 0) 21.15c 0.48c 0.32 [0.12 to 20.81] 21.28 0.66 0.28 [0.08–1.01]
Visits in corticosteroid-free remission, PGA ($1 versus 0)d 20.87c 0.36 0.42 [0.21 to 20.86] 20.71 0.51 0.49 [0.18–1.35]
Visits in remission, sPCDAI ($1 versus 0) 21.08b 0.29 0.34 [0.19 to 20.60] 20.47 0.42 0.62 [0.27–1.42]
Visits in corticosteroid-free remission, sPCDAI ($1 versus 0)d 20.91e 0.28 0.40 [0.23 to 20.70] 20.35 0.40 0.71 [0.32–1.54]
Growth at 1 year (satisfactory versus not) 20.43 0.43 0.65 [0.28 to 21.51] 21.88e 0.70 0.15 [0.04–0.60]
PGA at dx (in remission versus not) 20.09 0.30 0.91 [0.50 to 21.65] 20.49 0.45 0.61 [0.25–1.47]
PGA at 1 year (in remission versus not) 20.60c 0.30 0.55 [0.30 to 20.99] 20.32 0.41 0.73 [0.33–1.61]
Hematocrit at dxd 21.72e 0.64 22.08e 0.78
Hematocrit at 1 yeard 21.19 0.66 21.21 1.00
Albumin at dx 20.26e 0.09 20.27c 0.12
Albumin at 1 yeard 20.21e 0.07 20.42b 0.12
Reference groups: White race and commercial payor status. Remission status according to PGA and sPCDAI.
aOdds ratios (ORs) (exponentiated beta values) are presented for logistic regression on categorical outcomes only.
bP , 0.001.
cP , 0.05.
dAge was a covariate.
eP , 0.01.
dx, diagnosis.
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that may explain such long delays to the first visit include (1) patients
who were new to an ICN center but not newly diagnosed with CD,
and (2) that most patients at a center were there for a long period
before the center joining and recruiting subjects for the registry. As
ICN attempts to standardize care to some degree, there may be more
racial variation in the real world than within the ICN community. We
were unable to adjust for income and, thus, cannot separate the
effects of race from the effects of income or socioeconomic status.
The results of this study cannot be generalized to other racial or
ethnic minority groups. PGA is commonly used to assess clinical
remission. Although endoscopic remission or potentially even fecal
calprotectin would be a more rigorous endpoint, there are no
sufficient data to use that as an outcome metric in this study. The
key strengths of this study are that it is a large, regionally diverse,
multicenter study; the data are prospectively and longitudinally
collected, and it represents our day-to-day outpatient experience (as
opposed to results from administrative data sets, etc.).
In summary, this study identified several racial and few
socioeconomic disparities in pediatric patients with CD, including
differences in 1-year remission rate, despite similar treatment. The
significance of and reasons for these disparities require further
investigation. Multicenter, prospective studies would be helpful in
clarifying the role of socioeconomic, genetic, psychosocial, and
other factors that could contribute to these findings.
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